<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36727514</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1654</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Reviews in medical virology</Title><ISOAbbreviation>Rev Med Virol</ISOAbbreviation></Journal><ArticleTitle>The immune paradox of SARS-CoV-2: Lymphocytopenia and autoimmunity evoking features in COVID-19 and possible treatment modalities.</ArticleTitle><Pagination><StartPage>e2423</StartPage><MedlinePgn>e2423</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/rmv.2423</ELocationID><Abstract><AbstractText>SARS-CoV-2 causes multiorgan damage to vital organs and tissue that are known to be due to a combination of tissue tropisms and cytokine-mediated damage that it can incite in COVID-19. The effects of SARS-Co-2 on the lymphocytes and therefore on the immune response have attracted attention recently in COVID-19 to understand its effects in causing a chronic state of ongoing infection with Long-COVID. The associated lymphopaenia and autoimmune disease state, which is an apparent paradox, needs to be researched to dissect possible mechanisms underlying this state. This paper attempts to unravel the aforesaid immune paradox effects of SARS-CoV-2 on the lymphocytes and discusses appropriate treatment modalities with antiviral drugs and nutraceuticals which could prove virucidal in SARS-CoV-2 seeding monocytes and lymphocytes in patients with COVID-19 and Long-COVID. Importantly it proposes a new in vitro treatment modality of immune regulating cells that can help patients fight the lymphopaenia associated with COVID-19 and Long-COVID.</AbstractText><CopyrightInformation>&#xa9; 2023 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gerlach</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Health-Shield, Langenfeld, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baig</LastName><ForeName>Abdul Mannan</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-0626-216X</Identifier><AffiliationInfo><Affiliation>Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabrowski</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Royal Sussex County Hospital, University Hospitals Sussex, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viduto</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Long-COVID Foundation, Leeds, West Yorkshire, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rev Med Virol</MedlineTA><NlmUniqueID>9112448</NlmUniqueID><ISSNLinking>1052-9276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008231" MajorTopicYN="Y">Lymphopenia</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36727514</ArticleId><ArticleId IdType="doi">10.1002/rmv.2423</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3-20. https://doi.org/10.1038/s41580-021-00418-x</Citation></Reference><Reference><Citation>Bayati A, Kumar R, Francis V, McPherson PS. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. J Biol Chem. 2021;296:100306. https://doi.org/10.1016/j.jbc.2021.100306</Citation></Reference><Reference><Citation>Shang J, Wan Y, Luo C, et&#xa0;al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA. 2020;117(21):11727-11734. https://doi.org/10.1073/pnas.2003138117</Citation></Reference><Reference><Citation>Baig AM. Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci. 2020;11(24):4017-4020. https://doi.org/10.1021/acschemneuro.0c00725</Citation></Reference><Reference><Citation>Shi Y, Wang Y, Shao C, et&#xa0;al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-1454. https://doi.org/10.1038/s41418-020-0530-3</Citation></Reference><Reference><Citation>Ni Y, Alu A, Lei H, Wang Y, Wu M, Wei X. Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Mol Biomed. 2021;2(1):1. https://doi.org/10.1186/s43556-020-00015-y</Citation></Reference><Reference><Citation>Jafarzadeh A, Jafarzadeh S, Nozari P, Mokhtari P, Nemati M. Lymphopenia an important immunological abnormality in patients with COVID-19: possible mechanisms. Scand J Immunol. 2021;93(2):e12967. https://doi.org/10.1111/sji.12967</Citation></Reference><Reference><Citation>Rojas M, Rodr&#xed;guez Y, Acosta-Ampudia Y, et&#xa0;al. Autoimmunity is a hallmark of post-COVID syndrome. J Transl Med. 2022;20(1):129. https://doi.org/10.1186/s12967-022-03328-4</Citation></Reference><Reference><Citation>Taeschler P, Cervia C, Zurbuchen Y, et&#xa0;al. Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures. Allergy. 2022;77(8):2415-2430. https://doi.org/10.1111/all.15302</Citation></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et&#xa0;al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100. https://doi.org/10.1016/j.jtauto.2021.100100</Citation></Reference><Reference><Citation>Lucchese G, Vogelgesang A, Boesl F, et&#xa0;al. Anti-neuronal antibodies against brainstem antigens are associated with COVID-19. EBioMedicine. 2022;83:104211. https://doi.org/10.1016/j.ebiom.2022.104211</Citation></Reference><Reference><Citation>Baig AM, Khaleeq A, Ali U, Syeda H Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995-998. https://doi.org/10.1021/acschemneuro.0c00122</Citation></Reference><Reference><Citation>Shen XR, Geng R, Li Q, et&#xa0;al. ACE2-independent infection of T lymphocytes by SARS-CoV-2. Sig Transduct Target Ther. 2022;7(1):83. https://doi.org/10.1038/s41392-022-00919-x</Citation></Reference><Reference><Citation>Wang K, Chen W, Zhang Z, et&#xa0;al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Sig Transduct Target Ther. 2020;5(1):283. https://doi.org/10.1038/s41392-020-00426-x</Citation></Reference><Reference><Citation>Davanzo G &amp; Codo A &amp; Brunetti N, et&#xa0;al. (2020). SARS-CoV-2 uses CD4 to infect T helper lymphocytes. https://doi.org/10.1101/2020.09.25.20200329</Citation></Reference><Reference><Citation>Behl T, Kaur I, Aleya L, et&#xa0;al. CD147-spike protein interaction in COVID-19: get the ball rolling with a novel receptor and therapeutic target. Sci Total Environ. 2022;808:152072. https://doi.org/10.1016/j.scitotenv.2021.152072</Citation></Reference><Reference><Citation>Pontelli MC, Castro IA, Martins RB, et&#xa0;al. Infection of human lymphomononuclear cells by SARS-CoV-2. bioRxiv [Preprint]. 2020.28.225912. https://doi.org/10.1101/2020.07.28.225912</Citation></Reference><Reference><Citation>Illg Z, Muller G, Mueller M, Nippert J, Allen B. Analysis of absolute lymphocyte count in patients with COVID-19. Am J Emerg Med. 2021;46:16-19. https://doi.org/10.1016/j.ajem.2021.02.054</Citation></Reference><Reference><Citation>Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J intensive care. 2020;8(1):36. https://doi.org/10.1186/s40560-020-00453-4</Citation></Reference><Reference><Citation>Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. Lymphopenia during the COVID-19 infection: what it shows and what can be learned. Immunol Lett. 2020;225:31-32.&#xa0;https://doi.org/10.1016/j.imlet.2020.06.013</Citation></Reference><Reference><Citation>Rezaei M, Marjani M, Mahmoudi S, Mortaz E, Mansouri D. Dynamic changes of lymphocyte subsets in the course of COVID-19. Int Arch Allergy Immunol. 2021;182(3):254-262. https://doi.org/10.1159/000514202</Citation></Reference><Reference><Citation>Gozzi-Silva SC, Oliveira LM, Alberca RW, et al. Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients. Cells. 2022;11(21):3359. https://doi.org/10.3390/cells11213359</Citation></Reference><Reference><Citation>Wang Z, Yang L, Chen Y, Xu Z, Wang H, Zhang X. A longitudinal follow-up of COVID-19 patients in the convalescent phase showed recovery in radiological results, the dynamics of lyphocytes and a decrease in the level of IgG antibody: a single-centre, observational study. J Thorac Dis. 2021;13(5):2986-3000. https://doi.org/10.21037/jtd-20-3011</Citation></Reference><Reference><Citation>Murphy WJ, Longo DL. A possible role for anti-idiotype antibodies in SARS-CoV-2 infection and vaccination. N Engl J Med. 2022;386(4):394-396. https://doi.org/10.1056/NEJMcibr2113694</Citation></Reference><Reference><Citation>Buxeraud J, Faure S, Fougere &#xc9;. Le nirmatrelvir-ritonavir (Paxlovid&#xae;), un traitement contre la Covid-19 [Nirmatrelvir/ritonavir (Paxlovid&#xae;), a treatment for Covid-19]. Actual Pharmacol 2022;61(617):10-12. French. https://doi.org/10.1016/j.actpha.2022.05.002</Citation></Reference><Reference><Citation>Burki T. The future of Paxlovid for COVID-19. Lancet Respir Med. 2022;10(7):e68. https://doi.org/10.1016/S2213-2600(22)00192-8</Citation></Reference><Reference><Citation>Coulson JM, Adams A, Gray LA, Evans A. COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy. J Infect. 2022;85(4):436-480. https://doi.org/10.1016/j.jinf.2022.06.011</Citation></Reference><Reference><Citation>Charness M, Gupta K, Stack G, et&#xa0;al. Rapid relapse of symptomatic omicron SARS CoV-2 infection following early suppression with nirmatrelvir/ritonavir. 13 May 2022, PREPRINT (Version 2) https://doi.org/10.21203/rs.3.rs-1588371/v2. [CrossRef].</Citation></Reference><Reference><Citation>Carlin AF, Clark AE, Chaillon A, et&#xa0;al. Virologic and immunologic characterization of COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. 2022. https://doi.org/10.21203/rs.3.rs-1662783/v1. [PMC free article] [PubMed] [CrossRef].</Citation></Reference><Reference><Citation>COVID-19 Rebound after Paxlovid Treatment. CDCHAN-00467. 24th May 2022. Accessed on 26th May 2022 at.https://emergency.cdc.gov/han/2022/han00467.asp</Citation></Reference><Reference><Citation>Minami R, Takahama S, Kaku Y, Yamamoto M. Addition of Maraviroc to antiretroviral therapy decreased interferon-&#x3b3; mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery. J Infect Chemother. 2017;23(1):29-34. https://doi.org/10.1016/j.jiac.2016.09.003</Citation></Reference><Reference><Citation>Patterson BK, Guevara-Coto J, Yogendra R, et&#xa0;al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol. 2021;12:700782. https://doi.org/10.3389/fimmu.2021.700782</Citation></Reference><Reference><Citation>A Clinical Trial to Evaluate the Effectiveness and Safety of Vedicinals-9-A Herbal Formulation in Mild to Moderate COVID-19 Patients. CTRI; 12-10-2020; TrialI D: CTRI/2020/10/028364. https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ictrp-CTRI202010028364 (Accessed on 14th August 2022).</Citation></Reference><Reference><Citation>Interventional (Clinical Trial); ClinicalTrials.Gov Identifier: NCT04452799. Hesperidin and Diosmin for Treatment of COVID-19. https://clinicaltrials.gov/ct2/show/NCT04452799. (Accessed on 14th August 2022).</Citation></Reference><Reference><Citation>Cheng FJ, Huynh TK, Yang CS, et&#xa0;al. Hesperidin is a potential inhibitor against SARS-CoV-2 infection. Nutrients. 2021;13(8):2800. https://doi.org/10.3390/nu13082800</Citation></Reference><Reference><Citation>Haggag YA, El-Ashmawy NE, Okasha KM. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection? Med Hypotheses. 2020;144:109957. https://doi.org/10.1016/j.mehy.2020.109957</Citation></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its Relationship to epstein-Barr virus reactivation. Pathogens. 2021;10(6):763. https://doi.org/10.3390/pathogens10060763</Citation></Reference><Reference><Citation>Zhou X, Ye G, Lv Y, et&#xa0;al. IL-6 drives T cell death to participate in lymphopenia in COVID-19. Int Immunopharm. 2022;111:109132. https://doi.org/10.1016/j.intimp.2022.109132</Citation></Reference><Reference><Citation>Rahimmanesh I, Kouhpayeh S, Azizi Y, Khanahmad H. Conceptual framework for SARS-CoV-2-related lymphopenia. Adv Biomed Res. 2022;11:16. https://doi.org/10.4103/abr.abr_303_20</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>